May. 13 at 5:53 PM
$TSLA ONEMORE WINNER
RIGL As of May 13, 2026, Citi raised its price target on Rigel Pharmaceuticals (RIGL) to
$81 from
$69, maintaining a Buy rating. This upgrade reflects a bullish outlook on the company's growth strategy, specifically noting the in-licensing of Veppanu as a major expansion beyond its core hematology business .5X COMING